# US 2016/0256438 A1 · CATALYTIC SCAVENGERS OF ORGANOPHOSPHATES TO POTENTIATE BUTYRYLCHOLINESTERASE (hBChE) AS A CATALYTIC BIOSCAVENGER AND METHODS FOR MAKING AND USING THEM

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256438 A1
- Document ID: US20160256438A1
- Status: Published application
- Kind: A1
- Application number: 15/028,669
- Filed: 2014-10-15
- Published: 2016-09-08
- Earliest claimed: 2013-10-15
- Assignees: The Regents of the University of California; The Scripps Research Institute
- Applicants: The Regents of the University of California; The Scripps Research Institute
- Inventors: Palmer TAYLOR; Zoran RADIC; Valery FOKIN
- Web page: https://patentgrep.com/patent/US20160256438A1

## CPC

- A61K 31/4164: 1,3-Diazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/00: General protective or antinoxious agents
- C12Y 301/01008: Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Provided are N-alkyl imidazole 2-aldoximes, including cationic imidazolium and uncharged tertiary imidazole aldoximes, and compositions and methods for making and using them, including methods for reactivating human butyrylcholinesterase (hBChE) or acetylcholinesterase (hAChE) inhibited by organophosphate (OP). By administration of a composition of the invention, the inactive or conjugated hBChE-OP or hAChE-OP is reactivated and the catalytic cycle of turnover and inactivation of the OP is completed; and in alternative embodiments, secondary mechanisms of reversible protection of hBChE and hAChE from irreversible inactivation by OPs and reactivation of tissue AChE also contribute to overall efficacy.

## Claims

### Claim at position 1

1: A compound, composition or formulation comprising:
(a) a compound having a formula selected from the group consisting Formula I
wherein:
R1 is selected from the group consisting of: —H, —OH, -alkyl, -aryl, —O-alkyl, and —O-aryl, wherein optionally the alkyl is selected from the group consisting of: -methyl, -ethyl, -propyl, -butyl, -i-propyl, and -i-butyl), wherein optionally the aryl is selected from the group consisting of: -phenyl, -naphthyl, -thienyl, and -indolyl;
R2 is selected from the group consisting of: —H, —OH, -alkyl, -aryl, —O-alkyl, and —O-aryl, wherein optionally the alkyl is selected from the group consisting of: -methyl, -ethyl, -propyl, -butyl, -i-propyl, and -i-butyl, wherein optionally the aryl is selected from the group consisting of: -phenyl, -naphthyl, -thienyl, and -indolyl;
R3 is selected from the group consisting of:
H,
alkyl, wherein optionally the alkyl is selected from the group consisting of: -methyl, -ethyl, -propyl, -butyl, -i-propyl, and -i-butyl,
cycloalkyl, wherein optionally the cycloalkyl is selected from the group consisting of: -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -cycloheptyl, and cyclooctyl,
aryl, wherein optionally the aryl is selected from the group consisting of: -phenyl, -naphthyl, -thienyl, and -indolyl,
a saturated heterocyclic and/or a nonsaturated heterocyclic, wherein optionally the saturated heterocyclic and/or a nonsaturated heterocyclic is selected from the group consisting of: -aziridine, -oxirane-thiirane, -azirine, -oxirene, -thiirene, -azetidine, -oxetane, -thietane, -azete, -oxete, -thiete, -pyrrolidine, -oxolane, -thiolane, -pyrrole, -furan, -thiophene, -piperidine, -oxane, -thiane, -pyridine, -pyran, -thiopyran, -azepane, -oxepane, -thiepane, -azepine, -oxepine, -thiepine, -azocane, and -azocine,
a bridged compound, wherein optionally the bridged compound is selected from the group consisting of: -adamantanes, -amantadines, -biperidenes, -memantines, -methenamines, -rimantadines, -norbornanes, and -triazoles, and
a structure selected from the group consisting of:
and
R4 is selected from the group consisting of: —H, —OH, -alkyl, -aryl, —O-alkyl, and —O-aryl, wherein optionally the alkyl is selected from the group consisting of: -methyl, -ethyl, -propyl, -butyl, -i-propyl, and -i-butyl, wherein optionally the aryl is selected from the group consisting of: -phenyl, -naphthyl, -thienyl, and -indolyl;
(b) an N-alkyl imidazole 2-aldoxime capable of forming a zwitterion, or, a quaternary N-alkyl methyl imidazolium 2-aldoxime;
(c) an analog of any of (a) or (b), wherein optionally the analog comprises a structure of any of (a) or (b) wherein another heterocycle replaces the imidazole or imidazolium ring and/or a different alkyl substitution is made at the 1 and 3 nitrogen positions, or a substitution is made at the 4 and 5 positions of the imidazole or imidazolium rings;
(d) a bioisostere of any of (a), (b) or (c), wherein optionally one or more hydrogen atom(s) are replaced with one or more fluorine atom(s);
(e) a salt of, or a pharmaceutically acceptable salt of, any of (a), (b) or (c), wherein optionally the salt comprises a mesylate or a methane sulfonate salt; or
(f) any combination thereof.

### Claim at position 2 (depends on 1)

2: The compound, composition or formulation of claim 1, having a structure or formula selected from the group consisting of:
(a) a structure or formula selected from the group consisting of:
and
(b) a structure or formula of (a), wherein the anion I− is replaced by another anion or a negatively charged molecule or moiety.

### Claim at position 3 (depends on 1)

3: The compound, composition or formulation of claim 1, wherein the compound, composition or formulation is formulated for administration in vivo; or for enteral or parenteral administration, or for ophthalmic, topical, oral, intravenous (IV), intramuscular (IM), intrathecal, subcutaneous (SC), intracerebral, epidural, intracranial or rectal administration, or by inhalation.

### Claim at position 4 (depends on 1)

4: The compound, composition or formulation of claim 1, wherein the compound, composition or formulation is formulated as: a particle, a nanoparticle, a liposome, a tablet, a pill, a capsule, a gel, a geltab, a liquid, a powder, suspension, a syrup, an emulsion, a lotion, an ointment, an aerosol, a spray, a lozenge ophthalmic preparation, an aqueous or a sterile or an injectable solution, a patch (optionally a transdermal patch or a medicated adhesive patch), or an implant.

### Claim at position 5 (depends on 1)

5: A pharmaceutical composition or formulation comprising a compound, composition or formulation of claim 1, wherein optionally the pharmaceutical composition or formulation further comprises a pharmaceutically acceptable excipient.

### Claim at position 6 (depends on 5)

6: The pharmaceutical composition or formulation of claim 5, further comprising: (a) a butyrylcholinesterase (BChE), wherein optionally the BChE comprises a human butyrylcholinesterase (hBChE), or optionally the butyrylcholinesterase (BChE) comprise a recombinant BChE (rBChE) or a peptidomimetic BChE; or, (b) one or more additional drugs or formulations, wherein optionally the additional drug or formulation comprises a muscarinic acetylcholine receptor antagonist (a muscarinic antagonist) (optionally atropine), an anticonvulsant (optionally benzodiazapene or diazepam), a pralidoxime (or 2-pyridine aldoxime methyl chloride, or 2-PAM) or a combination thereof.

### Claim at position 7 (depends on 1)

7: A product of manufacture or a device, comprising a compound, composition or formulation of claim 1,
wherein optionally the product of manufacture or device is a medical device or an implant,
wherein optionally the product of manufacture or device is designed to be capable of injecting, causing inhalation of, adsorption of, or otherwise administering for either enteral or parenteral administration a compound, composition or formulation of claim 1.

### Claim at position 8 (depends on 1)

8: A pump, a patch, a device, a subcutaneous infusion device, a continuous subcutaneous infusion device, an infusion pen, a needles, a reservoir, an ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound, composition or formulation of claim 1.

### Claim at position 9 (depends on 1)

9: A method for:
reactivating a butyrylcholinesterase (BChE) or an acetylcholinesterase (AChE or acetylhydrolase) inhibited by or conjugated to an ester of a phosphoric acid (EPA) or an organophosphate (OP),
reactivating a BChE-OP or BChE-EPA conjugate or AchE-OP conjugate, protecting against irreversible inhibition of plasma or tissue BChE or AChE arising from an exposure to an organophosphate (OP), wherein optionally the exposure to is a bolus exposure to OP,
ameliorating, diminishing, reversing, treating or preventing the toxic effects of an ester of a phosphoric acid (EPA) or an organophosphate (OP),
wherein optionally the BChE comprises a human butyrylcholinesterase (hBChE) or the AChE comprises an acetylcholinesterase (h AChE),
and optionally the reactivating is in vitro or in vivo, or the protecting is in vivo, comprising:
(a) providing a compound, composition or formulation of claim 1; and
(b) contacting a BChE-OP, AChE-OP or BChE-EPA conjugate (which optionally is an hBChE-OP, h AChE-OP or hBChE-EPA conjugate with the compound, composition or formulation of claim 1, or
administering or applying to an individual in need thereof a compound, composition or formulation of claim 1,
wherein optionally the individual is a human,
and optionally the contacting, administering or applying is as a single or as multiple bolus or dosage unit administrations, or as continuous contacting,
administrations or applications, or any combination thereof, optionally including two or forms of contacting, administering or applying, optionally an IV, IM, oral and/or ophthalmic contacting, administering or applying in conjunction with, before and/or followed by a patch, a device controlled release or an IV infusion administration,
thereby:
reactivating the butyrylcholinesterase (BChE) or an acetylcholinesterase (AChE or acetylhydrolase) inhibited by or conjugated to an ester of a phosphoric acid (EPA) or an organophosphate (OP),
reactivating the BChE-OP or BChE-EPA conjugate or AchE-OP conjugate,
protecting against irreversible inhibition of plasma or tissue BChE or AChE arising from an exposure to an organophosphate (OP), and/or
ameliorating, diminishing, reversing, treating or preventing the toxic effects of an ester of a phosphoric acid (EPA) or an organophosphate (OP).

### Claim at position 10 (depends on 9)

10: The method of claim 9, wherein the contacting is in vitro or in vivo.

### Claim at position 11 (depends on 9)

11: The method of claim 9, wherein the organophosphate (OP) is a toxin, an herbicide, an insecticide, a pesticide, or a nerve gas or nerve agent,
and optionally the organophosphate (OP) is a parathion, a malathion, a methyl parathion, a chlorpyrifos, a diazinon, a dichlorvos, a phosmet, a fenitrothion, a tetrachlorvinphos, an azamethiphos or an azinphos methyl,
and optionally the OP or nerve agent comprises: a soman (O-Pinacolyl methyl phosphono fluoridate); a tabun (also called GD) (ethyl N,N-Dimethyl phosphoramido cyanidate); a sarin ((R5)-propan-2-yl methylphosphonofluoridate); a cyclosarin ((RS)-cyclohexyl methylphosphonofluoridate); an O-ethyl S-[2-(diisopropyl amino) ethyl]methylphosphonothioate (also called VX); or, an N,N-diethyl-2-(methyl-(2-methyl propoxy)phosphoryl) sulfanylethanamine (also called VR, or Russian VX).

### Claim at position 12 (depends on 9)

12: The method of claim 9, wherein the compound, composition or formulation, is co-administered with (optionally administered before, in conjunction with, and/or after administration of): (a) a butyrylcholinesterase (BChE), wherein optionally the BChE comprises a human butyrylcholinesterase (hBChE), or optionally the butyrylcholinesterase (BChE) comprise a recombinant BChE (rBChE) or a peptidomimetic BChE; or, (b) one or more additional drugs or formulations, wherein optionally the additional drug or formulation comprises a muscarinic acetylcholine receptor antagonist (a muscarinic antagonist) (optionally atropine), an anticonvulsant (optionally benzodiazapene or diazepam), a pralidoxime (or 2-pyridine aldoxime methyl chloride, or 2-PAM) or a combination thereof.

### Claim at position 13 (depends on 9)

13: The method of claim 9, wherein the compound, composition or formulation, is administered or applied before OP exposure, optionally at least between about 1 to 60 minutes, or between about 15 to 30 min, before OP exposure, and then optionally is administered or applied with more of the mixture immediately after the exposure, or optionally is administered or applied with more of the mixture in intervals after the exposure.

### Claim at position 14 (depends on 1)

14: A kit comprising a compound, composition or formulation of claim 1.

### Claim at position 15

16-17. (canceled)

### Claim at position 16 (depends on 1)

17: A combination, drug combination, or a therapeutic combination comprising:
(a) a compound, composition or formulation of claim 1; and
(b)
(i) a butyrylcholinesterase (BChE), wherein optionally the BChE comprises a human butyrylcholinesterase (hBChE), or optionally the butyrylcholinesterase (BChE) comprise a recombinant BChE (rBChE) or a peptidomimetic BChE;
(ii) one or more additional drugs or formulations,
wherein optionally the additional drug or formulation comprises a muscarinic acetylcholine receptor antagonist (a muscarinic antagonist) (optionally atropine), an anticonvulsant (optionally benzodiazapene or diazepam), a pralidoxime (or 2-pyridine aldoxime methyl chloride, or 2-PAM) or a combination thereof; or
(iii) any combination thereof.
